NASDAQ NMS - GLOBAL MARKET · PTGX
-0.21% · -$0.3100 · Vol 321.1K
Market closed · last close 4:00 PM ET · price as of 16:00:36 ET
Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Biotechnology
$145.87
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
PTGX
Protagonist Therapeutics Inc
Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

73/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PTGX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PTGX catalysts
About Protagonist Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2016
Employees
141
Country
US

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$146.18
Day high
$147.32
Day low
$144.44
Previous close
$146.18
52W high
$147.32
-0.98% from high
52W low
$51.07
98% of range
Market cap
$9.4B
P/E
124.68×
EPS
$1.17
Beta
0.59
Shares out
64.7M
Volume
321.1K
0.44× rel vol
Avg volume
726.9K
VWAP
$145.86
Price history computed in-house
1W
+6.75%
1M
+5.98%
3M
+46.81%
1Y
+185.63%
YTD
+67.01%
SMA 50 $123.41 · above
SMA 200 $98.87 · above
52W position 98%

PTGX overview

Veridion Score
73
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PTGX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PTGX Form 4 filings
Public disclosures

Congress activity in PTGX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PTGX in the cached public ledger.

Federal contracts

PTGX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PTGX in this window.
Lobbying spend

PTGX lobbying filings, year to date.

Registered lobbying filings matched to Protagonist Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PTGX in this window.
Loading news for PTGX
Analyst ratings
Sovereign unlock shows live analyst consensus for PTGX.
Options
Sovereign unlock shows live options positioning for PTGX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.